Unsurprisingly, more recent regimens for relapsed myeloma, which could favorably impact OS, such as chimeric antigen T‐cell therapy, T‐cell–engaging bispecific antibodies, and cereblon E3 ligase modulators, were rarely used in our cohort as they too were not approved in Canada during the study period. The gene discussed is CRBN; the disease is plasma cell myeloma.